The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma ‐Associated Raynaud's Phenomenon: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial Assessing
Conclusion
Our laboratory‐based LDI flow data do not support using Btx‐A to treat RP in all scleroderma patients. The secondary clinical outcomes suggest some positive, but questionably clinically meaningful effect. The role of Btx‐A in treating RP should be further studied with more homogeneous patient populations and in unique clinical situations like acute digital ischemia. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - Category: Rheumatology Authors: Ricardo J. Bello, Carisa M. Cooney, Eitan Melamed, Keith Follmar, Gayane Yenokyan, Gwendolyn Leatherman, Ami A. Shah, Fredrick M. Wigley, Laura K. Hummers, Scott D. Lifchez Tags: Full Length Source Type: research
More News: Arthritis | Clinical Trials | Eyes | Pain | Raynaud's Phenomenom | Rheumatology | Scleroderma | Statistics